Adam J. Townsend - 03 Oct 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Commercial Officer
Signature: /s/ David Watson, attorney-in-fact for Adam Townsend
Issuer symbol: APLS
Transactions as of: 03 Oct 2022
Net transactions value: -$258,000
Form type: 4
Filing time: 05 Oct 2022, 17:12:52 UTC
Previous filing: 07 Sep 2022
Next filing: 07 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$75,450	+5,000	+12%	$15.09	47,907	03 Oct 2022	Direct	F1
transaction	APLS	Common Stock	Sale	$333,450	-5,000	-10%	$66.69	42,907	03 Oct 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-1.6%	$0.000000	317,500	03 Oct 2022	Common Stock	5,000	$15.09	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale form an established 10b5-1 plan.
F2	This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.